TPWA
VRDN icon

Twin Peaks Wealth Advisors’s Viridian Therapeutics VRDN Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30
Closed -$587 – 2152
2026
Q1 		$587 Buy
+30
New +$891 ﹤0.01% 2007
2025
Q3 		– Sell
-26
Closed -$467 – 2079
2025
Q2 		$467 Buy
+26
New +$353 ﹤0.01% 1928

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Twin Peaks Wealth Advisors's VRDN Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 30 shares — an estimated $587 sold.

Twin Peaks Wealth Advisors first reported a position in VRDN in Q2 2025 and held it in 2 quarters. The position peaked at $587 in Q1 2026. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 30 Viridian Therapeutics shares in Q2 2026, an estimated $587.
  • Twin Peaks Wealth Advisors first reported a position in Viridian Therapeutics in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's Viridian Therapeutics position peaked at $587 in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.